Initial monotherapy and combination therapy and hypertension control the first year

Area of Science:

• Cardiology
• Pharmacology
• Public Health

Background:

• Clinical trials suggest single-pill combinations (SPCs) achieve faster blood pressure control than monotherapy.
• Lower blood pressure in the first treatment year is linked to better cardiovascular outcomes.
• Untreated, uncontrolled hypertension requires effective initial therapeutic strategies.

Purpose of the Study:

• To compare the effectiveness of initial antihypertensive monotherapy, free combinations, and SPCs in controlling blood pressure within the first year of treatment.
• To assess the impact of initial therapy choice on achieving blood pressure control targets.

Main Methods:

• Retrospective analysis of electronic health records from 180 practice sites.
• Inclusion of 106,621 adult patients with untreated, uncontrolled hypertension and at least one year of follow-up data.
• Blood pressure control defined by specific targets (<140/90 mmHg or <130/80 mmHg) based on comorbidities, analyzed using multivariable hazards regression.

Main Results:

• Patients initiating therapy with SPCs were more likely to have stage 2 hypertension at baseline.
• Initial SPC therapy demonstrated significantly higher odds of achieving blood pressure control within the first year compared to free combinations and monotherapy (HR 1.53 vs. 1.34 vs. 1.00).
• Benefits of SPCs were observed across both black and white patient populations.

Conclusions:

• Initial therapy with single-pill combinations significantly improves hypertension control during the first treatment year.
• Wider adoption of SPCs as initial therapy could lead to better patient outcomes and reduced cardiovascular events.
• The findings support the use of SPCs for rapid and effective management of newly diagnosed or uncontrolled hypertension.